These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20201884)

  • 1. PI3K kinase and scaffold functions in heart.
    Damilano F; Perino A; Hirsch E
    Ann N Y Acad Sci; 2010 Feb; 1188():39-45. PubMed ID: 20201884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac regulation by phosphoinositide 3-kinases and PTEN.
    Oudit GY; Penninger JM
    Cardiovasc Res; 2009 May; 82(2):250-60. PubMed ID: 19147653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of PI3 kinase gamma in excitation-contraction coupling and heart disease.
    Oudit GY; Kassiri Z
    Cardiovasc Hematol Disord Drug Targets; 2007 Dec; 7(4):295-304. PubMed ID: 18220729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A specific role of phosphatidylinositol 3-kinase gamma. A regulation of autonomic Ca(2)+ oscillations in cardiac cells.
    Bony C; Roche S; Shuichi U; Sasaki T; Crackower MA; Penninger J; Mano H; Pucéat M
    J Cell Biol; 2001 Feb; 152(4):717-28. PubMed ID: 11266463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide 3-kinase: friend and foe in cardiovascular disease.
    Ghigo A; Li M
    Front Pharmacol; 2015; 6():169. PubMed ID: 26321955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of phosphoinositide 3-kinases in regulating cardiac function.
    Pretorius L; Owen KL; McMullen JR
    Front Biosci (Landmark Ed); 2009 Jan; 14(6):2221-9. PubMed ID: 19273196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular toxicity of PI3Kα inhibitors.
    Sadasivan C; Zhabyeyev P; Labib D; White JA; Paterson DI; Oudit GY
    Clin Sci (Lond); 2020 Oct; 134(19):2595-2622. PubMed ID: 33063821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of phosphoinositide 3-kinase in cardiac function and heart failure.
    Naga Prasad SV; Perrino C; Rockman HA
    Trends Cardiovasc Med; 2003 Jul; 13(5):206-12. PubMed ID: 12837584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
    Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
    J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ.
    Martinez NG; Thieker DF; Carey LM; Rasquinha JA; Kistler SK; Kuhlman BA; Campbell SL
    J Mol Biol; 2021 Apr; 433(8):166838. PubMed ID: 33539876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure.
    Aoyagi T; Matsui T
    Curr Pharm Des; 2011; 17(18):1818-24. PubMed ID: 21631421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class I PI3K Biology.
    Aytenfisu TY; Campbell HM; Chakrabarti M; Amzel LM; Gabelli SB
    Curr Top Microbiol Immunol; 2022; 436():3-49. PubMed ID: 36243838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kα-Akt signaling.
    Yang L; Cai X; Liu J; Jia Z; Jiao J; Zhang J; Li C; Li J; Tang XD
    PLoS One; 2013; 8(4):e62373. PubMed ID: 23638055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific PI3K isoform modulation in heart failure: lessons from transgenic mice.
    Ghigo A; Morello F; Perino A; Damilano F; Hirsch E
    Curr Heart Fail Rep; 2011 Sep; 8(3):168-75. PubMed ID: 21519914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasostatin-1 Stops Structural Remodeling and Improves Calcium Handling via the eNOS-NO-PKG Pathway in Rat Hearts Subjected to Chronic β-Adrenergic Receptor Activation.
    Wang D; Shan Y; Huang Y; Tang Y; Chen Y; Li R; Yang J; Huang C
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):455-464. PubMed ID: 27595734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
    Oudit GY; Crackower MA; Eriksson U; Sarao R; Kozieradzki I; Sasaki T; Irie-Sasaki J; Gidrewicz D; Rybin VO; Wada T; Steinberg SF; Backx PH; Penninger JM
    Circulation; 2003 Oct; 108(17):2147-52. PubMed ID: 12963636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy during cardiac remodeling.
    Nishida K; Otsu K
    J Mol Cell Cardiol; 2016 Jun; 95():11-8. PubMed ID: 26678624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection.
    Weeks KL; Bernardo BC; Ooi JYY; Patterson NL; McMullen JR
    Adv Exp Med Biol; 2017; 1000():187-210. PubMed ID: 29098623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.
    Rathinaswamy MK; Burke JE
    Adv Biol Regul; 2020 Jan; 75():100657. PubMed ID: 31611073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.